Terizazole spray, its preparation method and application
By preparing terdizolam spray, and utilizing transdermal absorption enhancers and thickeners, the problem of slow onset of action at the affected area in existing formulations has been solved, achieving rapid and efficient therapeutic effects and improved safety.
Patent Information
- Application Number
- CN202510620955.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-05-14
- Publication Date
- 2026-11-17
AI Technical Summary
Existing terdizolamide phosphate tablets and injections have a slow onset of action at the affected area after systemic administration, resulting in numerous systemic adverse reactions and making them difficult to effectively treat acute bacterial skin and soft tissue infections.
A terdizolam spray is prepared, comprising an active ingredient, a thickener, a transdermal absorption enhancer, a lower alcohol solvent, an antibacterial agent, and a pH adjuster. It improves the local tissue concentration of the drug at the site of infection through transdermal absorption, thereby achieving rapid and uniform drug delivery.
It improved the treatment efficacy for acute bacterial skin and soft tissue infections, reduced systemic adverse reactions, and enhanced the drug's targeting and safety.
Smart Images

Figure CN123101469A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of pharmaceutical formulation technology, specifically relating to a terdizolam spray, its preparation method, and its application. Background Technology
[0002] Terizolamide is a new-generation oxazolidinone antibiotic, a derivative of the first-generation oxazolidinone antibiotic linezolid. Its mechanism of action involves binding to the 50S subunit of bacterial ribosomes to inhibit protein secretion, thereby exerting its antibacterial effect. Terizolamide possesses advantages such as strong antibacterial activity, high oral bioavailability, long half-life, and the ability to be administered without adjusting the dosage based on the function of the clearance organ or the route of administration. It also exhibits strong in vitro antibacterial activity against certain vancomycin- and linezolid-resistant strains, making it a relatively ideal antibacterial drug.
[0003] Terizolamide phosphate was initially developed by Dong-A Pharmaceutical in South Korea, and later commercialized by Merck and Bayer. It was first approved by the FDA in June 2014 and by the EU in June 2015. In March 2019, terizolamide phosphate tablets and injections were approved for marketing in China under the brand name "Sivextro". The approved indication is for the treatment of acute bacterial skin and soft tissue infections (ABSSSI) in adults caused by susceptible isolates of the following Gram-positive bacteria: Staphylococcus aureus (including isolates of methicillin-resistant Staphylococcus aureus [MRSA] and methicillin-sensitive Staphylococcus aureus [MSSA]), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus pharyngitis (including Streptococcus pharyngitis, Streptococcus intermedius, and Streptococcus constellations), and Enterococcus faecalis.
[0004] Acute bacterial skin and skin structure infections (ABSSSI) are lesions covering an area of at least 75 cm². 2 Bacterial infection (lesion area calculated based on the measured extent of congestion (erythema), edema, or induration); patients also present with systemic symptoms such as lymphadenopathy or fever (oral temperature ≥38℃). Types of ABSSSI infection include cellulitis / erysipelas, wound infection, and large skin abscess. In recent years, the isolation rate of Staphylococcus aureus in skin and soft tissue infections has been high, and community-acquired Staphylococcus aureus infections are becoming increasingly prevalent. Therefore, effective prevention and control of acute bacterial skin and soft tissue infections is a critical issue that urgently needs to be addressed.
[0005] Existing terdizolamide phosphate tablets and injections are both systemic formulations. After oral and intravenous administration, they are converted into terdizolamide, which enters the interstitial fluid of adipose and skeletal muscle tissues, with exposure levels similar to those of the free drug in plasma. Due to the relatively low blood flow to skin tissues, oral or intravenous administration of terdizolamide requires high doses and prolonged administration. After systemic absorption, it takes effect locally in the affected area, easily causing systemic adverse reactions. Therefore, the tissue distribution of terdizolamide is unfavorable for the treatment of acute bacterial skin and soft tissue infections using its oral or injectable formulations. Summary of the Invention
[0006] Based on this, the present invention provides a terdizolam spray. The spray is applied to the skin surface in a mist form, which is convenient to administer, has good uniformity, is absorbed quickly, and has a rapid onset of action. It can achieve efficient and uniform drug delivery, and through transdermal absorption, it increases the local tissue concentration of free drug at the site of bacterial infection, thereby better exerting its antibacterial activity, improving the therapeutic effect on local acute bacterial skin and soft tissue infections, reducing the systemic exposure of terdizolam, thereby reducing systemic adverse reactions and improving safety.
[0007] The present invention includes the following technical solutions.
[0008] In a first aspect, the present invention provides a terdiazole spray, the raw and excipients of which include an active ingredient, a thickener, a lower alcohol solvent, a transdermal absorption enhancer, an antibacterial agent, a pH adjuster, and water;
[0009] The active ingredient is terdizodil or its ester, or a pharmaceutically acceptable salt thereof;
[0010] The thickener is hydroxypropyl methylcellulose, for example, it can be one or more of hydroxypropyl methylcellulose E4M, hydroxypropyl methylcellulose K4M, hydroxypropyl methylcellulose F4M, hydroxypropyl methylcellulose K1500, hydroxypropyl methylcellulose K750, hydroxypropyl methylcellulose K250, and hydroxypropyl methylcellulose K100LV, preferably hydroxypropyl methylcellulose E4M.
[0011] The transdermal absorption enhancer is lauryl nitrogen. ketone;
[0012] The hydroxypropyl methylcellulose content in the terdizolam spray is 0.05% to 0.4% by weight.
[0013] Preferably, the hydroxypropyl methylcellulose in the terdizolam spray contains 0.05% to 0.3% by weight, more preferably 0.05% to 0.2%, more preferably 0.08% to 0.2%, more preferably 0.08% to 0.15%, and even more preferably 0.09% to 0.12%.
[0014] Preferably, the terdiazole spray has a dynamic viscosity of 20 mPa·s to 1000 mPa·s at 25°C, more preferably 30 mPa·s to 200 mPa·s, and even more preferably 50 mPa·s to 100 mPa·s.
[0015] Preferably, the pH of the terdizolam spray is adjusted to 6.5-8.5 using a pH adjuster, more preferably 7.0-8.5, and even more preferably 7.5-8.5.
[0016] Preferably, the transdermal absorption enhancer is present in the terdizolam spray at a weight content of 0.5%-8.0%, more preferably 0.5%-6.0%, more preferably 2.0%-6.0%, and even more preferably 2.0%-4.0%.
[0017] Preferably, the lower alcohol solvent is one or more of a monohydric alcohol or a polyhydric alcohol; more preferably, it is one or more of isopropanol, ethanol, propylene glycol and glycerol; the weight content of the lower alcohol solvent in the terdizolam spray is 20% to 42%, preferably 25% to 40%, more preferably 30% to 38%.
[0018] Preferably, the lower alcohol solvent is a combination of a monohydric alcohol and a polyhydric alcohol, wherein the monohydric alcohol is preferably isopropanol and the polyhydric alcohol is preferably propylene glycol; the mass ratio of the monohydric alcohol to the polyhydric alcohol is preferably 16-27:1.
[0019] Preferably, the active ingredient is terdizolam phosphate, and its weight content in the terdizolam spray is 0.1% to 5.0%, more preferably 0.5% to 3.0%, more preferably 0.5% to 2.5%, and even more preferably 1.5% to 2.5%.
[0020] Preferably, the antibacterial agent is selected from at least one of methylparaben, ethylparaben, propylparaben, butylparaben, benzyl alcohol, phenoxyethanol, sodium benzoate, potassium sorbate, benzalkonium chloride, and benzalkonium bromide; and its weight content in the terdizolam spray is 0.05% to 3.0%, preferably 0.05% to 2.2%.
[0021] Preferably, the pH adjuster is selected from at least one of sodium hydroxide, potassium hydroxide, triethanolamine, diisopropanolamine, aminomethylpropanol, aminobutanetriol and tetra-2-hydroxypropylethylenediamine, with sodium hydroxide being preferred.
[0022] Preferably, the raw materials and excipients of the terdizolam spray, by weight percentage, include:
[0023] Terizazole phosphate 0.5%–2.5%,
[0024] Hydroxypropyl methylcellulose 0.05%–0.4%,
[0025] Lower alcohol solvents 20%–42%,
[0026] Transdermal absorption enhancer 0.5%–8.0%,
[0027] Antibacterial agent 0.01%–3.0%,
[0028] An appropriate amount of pH adjuster is used to adjust the pH of the terdizolam spray to 6.5–8.5;
[0029] Add water to 100%;
[0030] The alcohol solvent is a combination of a monohydric alcohol and a polyhydric alcohol, wherein the monohydric alcohol is isopropanol and the polyhydric alcohol is propylene glycol.
[0031] Secondly, the present invention also provides a method for preparing the aforementioned terdizolam spray, comprising the following steps:
[0032] The thickener is added to the lower alcohol solvent, transdermal absorption enhancer, and antibacterial agent, and stirred until homogeneous. Then, some water and the active ingredient are added and stirred until homogeneous. The pH is adjusted with a pH adjuster, and finally, water is added to determine the weight, stirred until homogeneous, filtered, and filled to obtain the terdizolam spray.
[0033] Thirdly, the present invention provides the use of the aforementioned terdizolam spray in the preparation of a medicament for treating acute bacterial skin and soft tissue infections.
[0034] Fourthly, the present invention provides the use of the aforementioned terdizolam spray in the preparation of a medicament for treating skin tissue infections caused by methicillin-resistant Staphylococcus aureus.
[0035] The present invention has the following beneficial effects:
[0036] This invention relates to a topical spray prepared by combining terdizolam or its derivatives (e.g., esters) or pharmaceutically acceptable salts or mixtures thereof with specific thickeners, specific transdermal absorption enhancers, and other excipients. This terdizolam spray, by adding specific transdermal absorption enhancers, improves the skin penetration rate of the drug, allowing it to rapidly penetrate and act on the lesion site with strong targeting. Transdermal absorption increases the local tissue concentration of free drug at the site of bacterial infection, thereby better exerting its antibacterial activity, improving the therapeutic effect on local acute bacterial skin and soft tissue infections, reducing systemic exposure to terdizolam, thus reducing systemic adverse reactions and improving safety. Extensive pharmacological experiments have demonstrated that this terdizolam spray, when applied topically to bacterial skin infections, more effectively exerts the antibacterial activity of terdizolam, and its therapeutic effect on acute bacterial skin and soft tissue infections is significantly superior to terdizolam phosphate tablets and injectable terdizolam phosphate.
[0037] This invention creatively and for the first time prepares terdizolamide or its derivatives or its salts or mixtures thereof into a spray, overcoming the technical prejudice that terdizolamide cannot penetrate the stratum corneum when applied topically, improving the therapeutic effect of terdizolamide, reducing its systemic adverse reactions, facilitating clinical administration, meeting the interests of a large number of patients, and showing great application prospects.
[0038] Furthermore, by further optimizing and screening the thickener and its dosage, combined with further optimization of pH and lower alcohol solvents, the user experience and drug stability of terdizolam spray can be significantly improved, ensuring that the active drug does not degrade and its content remains stable during storage and use, thus guaranteeing its therapeutic concentration during medication. Attached Figure Description
[0039] Figure 1 Skin tissue pathological sections (HE, ×200) before administration on day 4; where A is the normal control group, B is the model control group, C is the injectable terdizolam phosphate model group, D is the terdizolam phosphate spray model group without transdermal absorption enhancer, and E is the terdizolam phosphate spray model group.
[0040] Figure 2 Skin tissue pathological sections (HE, ×200) taken the day after the last administration; where A is the normal control group, B is the model control group, C is the injectable terdizolam phosphate model group, D is the terdizolam phosphate spray model group without transdermal absorption enhancer, and E is the terdizolam phosphate spray model group. Detailed Implementation
[0041] To facilitate understanding of the present invention, a more complete description will be provided below. The present invention can be implemented in many different forms and is not limited to the embodiments described herein. Rather, these embodiments are provided to provide a thorough and complete understanding of the disclosure of the present invention.
[0042] Unless otherwise specified, experimental methods in the following examples are generally performed under standard conditions or as recommended by the manufacturer. All commonly used chemical reagents used in the examples are commercially available products.
[0043] Unless otherwise defined, all technical and scientific terms used in this invention have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. The terminology used in this specification is for the purpose of describing particular embodiments only and is not intended to limit the invention. The term "and / or" as used in this invention includes any and all combinations of one or more of the associated listed items.
[0044] Furthermore, as used herein, the term "or" is an inclusive "or" sign and is equivalent to the term "and / or" unless the context clearly specifies otherwise. The term "based on" is not exclusive and allows for basing on other factors not described unless the context clearly specifies otherwise. Additionally, throughout the specification, the meanings of "an," "a," and "the" include plural indicators. The meaning of "in" includes both "in" and "on."
[0045] Terizolamide inhibits bacterial growth by binding to the 23S site of the ribosomal RNA on the 50S subunit of bacteria, thereby preventing the formation of the 70S initiation complex and inhibiting bacterial protein synthesis. It is used to treat acute bacterial skin and soft tissue infections. Current dosage form research is mostly limited to terizolamide phosphate tablets or injectable terizolamide phosphate. After oral or intravenous administration, terizolamide phosphate is converted to terizolamide by intestinal or blood phosphatases, and then exerts its antibacterial effect through the aforementioned mechanism. However, both routes of administration carry the risk of systemic adverse reactions, and the drug concentration reaching the affected skin site after systemic circulation is limited, resulting in less than ideal therapeutic effects.
[0046] Meanwhile, current technology suggests that topical terizolamide cannot penetrate the stratum corneum of the skin and cannot reach an effective tissue concentration in the skin, thus failing to exert its therapeutic effect on acute bacterial skin and soft tissue infections. Therefore, although terizolamide or its pharmaceutically acceptable salts or mixtures thereof were launched in the United States as early as 2014, topical terizolamide formulations have not been available in China or abroad for nearly a decade.
[0047] In order to overcome the above-mentioned shortcomings of oral or intravenous administration, the inventors of this invention discovered through tireless research that by combining terdizolam or its derivatives or salts with appropriate thickeners, transdermal absorption enhancers and other excipients, a highly effective topical terdizolam spray can be prepared. In vitro pharmacodynamic studies have shown that it has unexpectedly excellent antibacterial activity in local skin bacterial infections, overcoming the technical prejudice that topical terdizolam cannot penetrate the stratum corneum of the skin.
[0048] This invention prepares terizolamide, its derivatives, its salts, or mixtures thereof into a topical spray. Extensive pharmacological experiments have demonstrated that this terizolamide spray, when applied topically to treat bacterial skin infections, effectively exerts the antibacterial activity of terizolamide. The terizolamide spray prepared by this invention, administered topically, exhibits excellent therapeutic effects on acute bacterial skin and soft tissue infections, significantly outperforming terizolamide phosphate tablets and injectable terizolamide phosphate. This indicates that the topical terizolamide phosphate spray prepared by this invention can be absorbed transdermally, increasing the local tissue concentration of free drug at the site of bacterial infection, thus better exerting its therapeutic effect on acute bacterial skin and soft tissue infections and reducing adverse reactions. This invention creatively and for the first time prepares terdizolamide or its pharmaceutically acceptable salts or mixtures thereof into a spray, overcoming the technical prejudice that terdizolamide cannot penetrate the stratum corneum when applied topically, improving the therapeutic effect of terdizolamide, reducing its systemic adverse reactions, meeting the interests of a large number of patients, and having a very good application prospect.
[0049] The above-mentioned effects of the terdiazole spray of the present invention are achieved through the following technical solutions.
[0050] In one embodiment of the present invention, a terdiazole spray is provided, comprising an active ingredient, a thickener, a lower alcohol solvent, a transdermal absorption enhancer, an antibacterial agent, a pH adjuster, and water;
[0051] The active ingredient is terdizodil or its ester, or a pharmaceutically acceptable salt thereof;
[0052] The thickener is hydroxypropyl methylcellulose, and the type of hydroxypropyl methylcellulose can be hydroxypropyl methylcellulose E4M, hydroxypropyl methylcellulose K4M, hydroxypropyl methylcellulose F4M, hydroxypropyl methylcellulose K1500, hydroxypropyl methylcellulose K750, hydroxypropyl methylcellulose K250, hydroxypropyl methylcellulose K100LV, etc., with hydroxypropyl methylcellulose E4M being preferred.
[0053] The transdermal absorption enhancer is lauryl nitrogen. ketone;
[0054] The hydroxypropyl methylcellulose content in the terdizolam spray is 0.05% to 0.4% by weight.
[0055] The content of hydroxypropyl methylcellulose in the terdizolam spray needs to ensure that the spray has the required viscosity, with a dynamic viscosity of 20 mPa·s to 1000 mPa·s at 25°C. The inventors have found that if the content of hydroxypropyl methylcellulose in the terdizolam spray is too high, the viscosity will be too high, leading to uneven spraying and significantly affecting the stability of the spray; conversely, if the content is too low, the viscosity will be too low, resulting in small spray particles, particle dispersion, reduced adhesion, and decreased efficacy. A terdizolam spray with a hydroxypropyl methylcellulose content of 0.05% to 0.4% (w / w) meets the usage requirements; when the hydroxypropyl methylcellulose content in the formulation is 0.5% (w / w), the viscosity of the terdizolam spray is too high, resulting in uneven spraying on the skin surface and also increasing the amount of related substances in the spray. Therefore, the content of hydroxypropyl methylcellulose in the terdizolam spray is preferably 0.05% to 0.4% (w / w), more preferably 0.05% to 0.3% (w / w), more preferably 0.05% to 0.2% (w / w), more preferably 0.08% to 0.2% (w / w), more preferably 0.08% to 0.15% (w / w), and even more preferably 0.09% to 0.12%.
[0056] The content of the active ingredient (terdizodil or its ester, or a pharmaceutically acceptable salt thereof) in the terdizodil spray can be determined according to therapeutic needs, and can be 0.1% to 5.0% (w / w), preferably 0.5% to 3.0% (w / w), more preferably 0.5% to 2.5% (w / w), and even more preferably 1.5% to 2.5% (w / w).
[0057] The active ingredient may be free terdizodil, terdizodil phosphate, or other pharmaceutically acceptable salts or esters.
[0058] The lower alcohol solvent in the terdiazole spray of the present invention can be a monohydric alcohol (e.g., isopropanol) or a polyhydric alcohol (e.g., propylene glycol).
[0059] In some embodiments, the content of the lower alcohol solvent in the terdizolam spray can be 20% to 42% (w / w), preferably 25% to 40% (w / w), and more preferably 30% to 38% (w / w). The content of the alcohol solvent also has a certain impact on the solubility and usability of the terdizolam spray. If the content is too high, the raw material will not dissolve completely; if the content is too low, water will drip from the surface of the spraying area. When the content is in the preferred range of 20% to 42% (w / w), the terdizolam spray has a suitable solubility and usability.
[0060] In some embodiments, the alcohol solvent is a combination of a monohydric alcohol and a polyhydric alcohol; wherein the monohydric alcohol is preferably isopropanol, and the polyhydric alcohol is preferably propylene glycol; the mass ratio of the monohydric alcohol to the polyhydric alcohol is preferably 16-27:1.
[0061] The transdermal absorption enhancer described in this invention is preferably lauryl nitrogen. Ketones can improve the transdermal absorption of terdiazole spray, thereby enhancing its antibacterial effect. The ketone content in terdiazole spray is 0.5%-8.0% by weight, preferably 0.5%-6.0%, more preferably 2.0%-6.0%, and even more preferably 2.0%-4.0%.
[0062] The antibacterial agent described in this invention can be a commonly used antibacterial agent acceptable in pharmaceuticals, such as methylparaben, ethylparaben, propylparaben, butylparaben, benzyl alcohol, phenoxyethanol, sodium benzoate, potassium sorbate, benzalkonium chloride, benzalkonium bromide, etc.
[0063] The content of the antibacterial agent in the terdiazole spray can be 0.01% to 3.0% (w / w), preferably 0.05% to 2.2% (w / w); when benzyl alcohol is used as the antibacterial agent, its content is preferably 1.2% to 2.2% (w / w); when benzalkonium chloride and / or benzalkonium bromide are used as the antibacterial agent, its content is preferably 0.01% to 0.03% (w / w).
[0064] The pH adjuster described in this invention can be an inorganic base or an organic base; the inorganic base can be, for example, sodium hydroxide, potassium hydroxide, etc.; the organic base can be a low-molecular-weight amine compound, such as triethanolamine, diisopropanolamine, aminomethylpropanol, aminobutanetriol, tetra-2-hydroxypropylethylenediamine; preferably sodium hydroxide.
[0065] The inventors discovered that the pH of terdiazole spray has a significant impact on its stability. Terdiazole spray with a pH of 6.5–8.5 exhibits better stability. When the pH is 6.0 or lower, or 8.6 or higher, the stability of terdiazole spray decreases significantly. After being placed under accelerated testing conditions (40°C / 75% RH) for 6 months, the API content degrades severely, and related substances increase significantly. Therefore, the pH of the terdiazole spray described in this invention needs to be adjusted using a pH adjuster. The preferred pH is 6.5–8.5, more preferably 7.0–8.5, and even more preferably 7.5–8.5.
[0066] In some embodiments, the raw materials and excipients of the terdizolam spray, by weight percentage, include:
[0067] Terizazole phosphate 0.5%–2.5%,
[0068] Hydroxypropyl methylcellulose 0.05%–0.4%,
[0069] Lower alcohol solvents 20%–42%,
[0070] Transdermal absorption enhancer 0.5%–8.0%,
[0071] Antibacterial agent 0.01%–3.0%,
[0072] An appropriate amount of pH adjuster is used to adjust the pH of the terdizolam spray to 6.5–8.5;
[0073] Add water to 100%;
[0074] The alcohol solvent is a combination of a monohydric alcohol and a polyhydric alcohol, wherein the monohydric alcohol is isopropanol and the polyhydric alcohol is propylene glycol.
[0075] In some embodiments, the raw materials and excipients of the terdizolam spray, by weight percentage, include:
[0076] Terizazole phosphate 1.5%–2.5%,
[0077] Hydroxypropyl methylcellulose 0.05%–0.2%,
[0078] Lower alcohol solvent 30%–38%,
[0079] Transdermal absorption enhancer 2.0%–4.0%,
[0080] Antibacterial agent 0.01%–2.2%,
[0081] An appropriate amount of pH adjuster is used to adjust the pH of the terdizolam spray to 7.0–8.5;
[0082] Add water to 100%;
[0083] The alcohol solvent is a combination of a monohydric alcohol and a polyhydric alcohol, wherein the monohydric alcohol is isopropanol and the polyhydric alcohol is propylene glycol.
[0084] The terdiazole spray of the present invention may also contain other excipients acceptable for sprays, such as one or more of antioxidants, chelating agents, and fragrances. Among them, antioxidants may be sodium bisulfite, butylated hydroxyanisole, dibutylhydroxytoluene, etc.; chelating agents may be ethylenediaminetetraacetic acid, disodium ethylenediaminetetraacetate, dicalcium ethylenediaminetetraacetate, tartaric acid, citric acid, etc.
[0085] In another embodiment of the present invention, a method for preparing the terdiazole spray of the present invention is provided, the method comprising the following steps:
[0086] The thickener is added to the lower alcohol solvent, transdermal absorption enhancer, and antibacterial agent, and stirred until homogeneous. Then, some water and the active ingredient are added and stirred until homogeneous. The pH is adjusted with a pH adjuster, and finally, water is added to determine the weight, stirred until homogeneous, filtered, and filled to obtain the terdizolam spray.
[0087] In another embodiment of the invention, the application of the terdizolam spray described herein is provided, which can be used for the treatment of acute bacterial skin and soft tissue infections or related diseases.
[0088] The present invention will be further described in detail below with reference to specific embodiments.
[0089] Example 1
[0090] The preparation method of the terdizolam phosphate spray provided in this embodiment is as follows:
[0091] Add 1g of hydroxypropyl methylcellulose E4M to 350g of isopropanol, 15g of propylene glycol, and 30g of lauryl nitrogen. Mix ketone and 16g benzyl alcohol thoroughly; then add 350g purified water and 20g terdiazole phosphate, and mix thoroughly; adjust the pH to 7.5 with sodium hydroxide solution, add an appropriate amount of purified water to make the total mass of the mixture 1000g, mix thoroughly, filter, and fill into vials to obtain the terdiazole spray.
[0092] Example 2
[0093] The difference between the terdizolam phosphate spray provided in this embodiment and that in Example 1 is that the hydroxypropyl methylcellulose is of type K4M and its dosage is 0.1% (w / w). The other components, dosages, and preparation methods are the same as in Example 1.
[0094] Example 3
[0095] The difference between the terdizolam phosphate spray provided in this embodiment and that in Example 1 is that the hydroxypropyl methylcellulose is of type F4M and its dosage is 0.1% (w / w). The other components, dosages, and preparation methods are the same as in Example 1.
[0096] Example 4
[0097] The difference between the terdizolam phosphate spray provided in this embodiment and that in Example 1 is that the hydroxypropyl methylcellulose is of the type K1500 and its dosage is 0.15% (w / w). The other components, dosages, and preparation methods are the same as in Example 1.
[0098] Example 5
[0099] The difference between the terdizolam phosphate spray provided in this embodiment and that in Example 1 is that the hydroxypropyl methylcellulose is of type K750 and its dosage is 0.18% (w / w). The other components, dosages, and preparation methods are the same as in Example 1.
[0100] Example 6
[0101] The difference between the terdizolam phosphate spray provided in this embodiment and that in Example 1 is that the hydroxypropyl methylcellulose is of type K250 and its dosage is 0.2% (w / w). The other components, dosages, and preparation methods are the same as in Example 1.
[0102] Example 7
[0103] The difference between the terdizolam phosphate spray provided in this embodiment and that in Example 1 is that the hydroxypropyl methylcellulose is of the type K100LV and its dosage is 0.2% (w / w). The other components, dosages, and preparation methods are the same as in Example 1.
[0104] Example 8
[0105] The difference between the terdizolam phosphate spray provided in this embodiment and that in Example 1 is that the pH of the finished product is adjusted to 6.5, while the other components, dosages, and preparation methods are the same as in Example 1.
[0106] Example 9
[0107] The difference between the terdizolam phosphate spray provided in this embodiment and that in Example 1 is that the pH of the finished product is adjusted to 8.5, while the other components, dosages, and preparation methods are the same as in Example 1.
[0108] Example 10
[0109] The difference between the terdizolam phosphate spray provided in this embodiment and that in Example 1 is that the amount of hydroxypropyl methylcellulose used is 0.05% (w / w), while the other components, amounts, and preparation methods are the same as in Example 1.
[0110] Example 11
[0111] The difference between the terdizolam phosphate spray provided in this embodiment and that in Example 1 is that the amount of hydroxypropyl methylcellulose used is 0.2% (w / w), while the other components, amounts, and preparation methods are the same as in Example 1.
[0112] Example 12
[0113] The difference between the terdizolam phosphate spray provided in this embodiment and that in Example 1 is that the proportion of isopropanol is 40%, while the other components, dosages, and preparation methods are the same as in Example 1.
[0114] Example 13
[0115] The difference between the terdizolam phosphate spray provided in this embodiment and that in Example 1 is that the proportion of isopropanol is 25%, while the other components, dosages, and preparation methods are the same as in Example 1.
[0116] Example 14
[0117] The terdizazole phosphate spray provided in this embodiment differs from that in Example 1 in that it contains lauryl nitrogen. The amount of ketone used was 1.0% (w / w), and the other components, amounts, and preparation methods were the same as in Example 1.
[0118] Example 15
[0119] The terdizazole phosphate spray provided in this embodiment differs from that in Example 1 in that it contains lauryl nitrogen. The amount of ketone used was 6.0% (w / w), and the other components, amounts, and preparation methods were the same as in Example 1.
[0120] Example 16
[0121] The terdizazole phosphate spray provided in this embodiment differs from that in Example 1 in that it contains lauryl nitrogen. The ketone content was 8%, and the other components, dosages, and preparation methods were the same as in Example 1.
[0122] Example 17
[0123] The difference between the terdizolam phosphate spray provided in this embodiment and that in Example 1 is that the amount of benzyl alcohol used is 1.2% (w / w), while the other components, amounts, and preparation methods are the same as in Example 1.
[0124] Example 18
[0125] The difference between the terdizolam phosphate spray provided in this embodiment and that in Example 1 is that the amount of benzyl alcohol used is 2.2% (w / w), while the other components, amounts, and preparation methods are the same as in Example 1.
[0126] Example 19
[0127] The difference between the terdiazole phosphate spray provided in this embodiment and that in Example 1 is that the antibacterial agent benzyl alcohol is replaced with benzalkonium chloride, which accounts for 0.01% (w / w). The other components, dosages, and preparation methods are the same as in Example 1.
[0128] Example 20
[0129] The terdiazole phosphate spray provided in this embodiment differs from that in Example 1 in that the antibacterial agent benzyl alcohol is replaced with benzalkonium chloride, which accounts for 0.03% (w / w). The other components, dosages, and preparation methods are the same as in Example 1.
[0130] Example 21
[0131] The terdiazole phosphate spray provided in this embodiment differs from that in Example 1 in that the antibacterial agent benzyl alcohol is replaced with benzalkonium bromide, with a dosage of 0.01% (w / w). The other components, dosages, and preparation methods are the same as in Example 1.
[0132] Example 22
[0133] The terdiazole phosphate spray provided in this embodiment differs from that in Example 1 in that the antibacterial agent benzyl alcohol is replaced with benzalkonium bromide, with a dosage of 0.03% (w / w). The other components, dosages, and preparation methods are the same as in Example 1.
[0134] Comparative Example 1
[0135] The terdizolam phosphate spray provided in this comparative example differs from that in Example 1 in that the formulation does not contain hydroxypropyl methylcellulose, while the other components, dosages, and preparation methods are the same as in Example 1.
[0136] Comparative Example 2
[0137] The terdizolam phosphate spray provided in this comparative example differs from that in Example 1 in that the amount of hydroxypropyl methylcellulose used is 0.5% (w / w), while the other components, amounts, and preparation methods are the same as in Example 1.
[0138] Comparative Example 3
[0139] The terdizolam phosphate spray provided in this comparative example differs from that in Example 1 in that the thickener in the formulation is hydroxyethyl cellulose M Pharm, while the other components, dosages, and preparation methods are the same as in Example 1.
[0140] Comparative Example 4
[0141] The terdizolam phosphate spray provided in this comparative example differs from that in Example 1 in that the thickener in the formulation is xanthan gum, while the other components, dosages, and preparation methods are the same as in Example 1.
[0142] Comparative Example 5
[0143] The terdizolam phosphate spray provided in this comparative example differs from that in Example 1 in that the pH of the finished product is adjusted to 6.0, while the other components, dosages, and preparation methods are the same as in Example 1.
[0144] Comparative Example 6
[0145] The terdizolam phosphate spray provided in this comparative example differs from that in Example 1 in that the pH of the finished product is adjusted to 9.0, while the other components, dosages, and preparation methods are the same as in Example 1.
[0146] Comparative Example 7
[0147] The terdizolam phosphate spray provided in this comparative example differs from that in Example 1 in that the proportion of isopropanol is 45%, while the other components, dosages, and preparation methods are the same as in Example 1.
[0148] Comparative Example 8
[0149] The terdizolam phosphate spray provided in this comparative example differs from that in Example 1 in that the proportion of isopropanol is 18%, while the other components, amounts, and preparation methods are the same as in Example 1.
[0150] Comparative Example 9
[0151] The terdizazole phosphate spray provided in this comparative example differs from that in Example 1 in that the formulation does not contain lauryl nitrogen. The ketone, other components and amounts, and preparation methods are the same as in Example 1.
[0152] Comparative Example 10
[0153] The terdizolam phosphate spray provided in this comparative example differs from that in Example 1 in that the transdermal absorption enhancer in the formulation is menthol, while the other components, dosages, and preparation methods are the same as in Example 1.
[0154] Comparative Example 11
[0155] The terdizolam phosphate spray provided in this comparative example differs from that in Example 1 in that the transdermal absorption enhancer in the formulation is isopropyl myristate, while the other components, dosages, and preparation methods are the same as in Example 1.
[0156] Example 23: Observation of Characteristics
[0157] The properties of the terdizolam phosphate sprays prepared in Examples 1-22 and Comparative Example 7 were observed visually. The results showed that, except for the terdizolam phosphate spray prepared in Comparative Example 7, which was a milky white suspension, the other terdizolam phosphate sprays were all colorless, clear, and transparent liquids.
[0158] Example 24 Viscosity Measurement
[0159] The viscosity of the terdiazole phosphate sprays prepared in Examples 1-22, Comparative Example 1, and Comparative Example 2 was determined. The method is as follows:
[0160] Take an appropriate amount of the corresponding terdiazole phosphate spray and let it stand at 25°C for at least 30 minutes. Test the viscosity using a rotational viscometer according to the viscosity determination method (Chinese Pharmacopoeia 2020 Edition, Part IV, General Chapter 0633, Method III). Measure the same sample three times and calculate the average value. The dynamic viscosity of the spray at 25°C should be 20–1000 mPa·s.
[0161] The viscosity test data are shown in Table 1 below: Within the range of 0.05% to 0.2% (w / w) of hydroxypropyl methylcellulose, the viscosity of different types of hydroxypropyl methylcellulose for terdizolam phosphate spray all meet the requirements. When the formulation does not contain hydroxypropyl methylcellulose, the viscosity of terdizolam phosphate spray is too low, causing particles to scatter and reducing the adhesion rate. The viscosity of terdizolam phosphate spray with a hydroxypropyl methylcellulose content of 0.5% (w / w) is relatively high, which will cause uneven spraying on the skin surface for this product.
[0162] Table 1
[0163]
[0164]
[0165] Note: The viscosity measurement temperature is 25℃.
[0166] Example 25 Usage
[0167] The terdiazole phosphate sprays prepared in Examples 1-22 and Comparative Example 8 were sprayed onto the forearm from a distance of 5 cm for 3 seconds, and the dripping state was observed and evaluated.
[0168] Table 2
[0169]
[0170]
[0171]
[0172] Example 26 Stability Test
[0173] The terdizolam phosphate sprays prepared in Examples 1, 8, 9, 12, 13, 2, 3, 4, 5, and 6 were subjected to accelerated stability testing (40℃ / 75%RH). The pH was determined according to the pH determination method (Chinese Pharmacopoeia 2020 Edition, Part IV, General Chapter 0631), and the related substances and contents of terdizolam phosphate in the sprays were determined according to the high performance liquid chromatography method (Chinese Pharmacopoeia 2020 Edition, Part IV, General Chapter 0512).
[0174] The experimental results are shown in Tables 3-6.
[0175] Stability studies revealed that the amount of hydroxypropyl methylcellulose (HPMC) significantly affected the stability of terdizolam phosphate spray. Terdizolam phosphate spray with 0.5% HPMC (Comparative Example 2) showed a significant increase in related substances after 6 months of accelerated testing (40℃ / 75% RH). Other thickeners, such as hydroxyethyl cellulose and xanthan gum, exhibited incompatibility with the active ingredient in terdizolam phosphate spray. Terdizolam phosphate sprays using hydroxyethyl cellulose and xanthan gum as thickeners (Comparative Examples 3 and 4) showed a significant increase in related substances after 6 months of accelerated testing (40℃ / 75% RH).
[0176] Stability tests of terdizolam phosphate spray under different pH conditions revealed that the stability of terdizolam phosphate spray is significantly affected by pH. Terdizolam phosphate sprays with pH values of 6.0 and 9.0 (Comparative Examples 5 and 6) showed severe degradation of API content and a significant increase in related substances after 6 months of accelerated testing (40℃ / 75%RH). In contrast, terdizolam phosphate sprays with pH values between 6.5 and 8.5 showed no significant change in content within 6 months under accelerated testing (40℃ / 75%RH), and the increase in related substances was controllable, indicating improved stability of the spray.
[0177] Terizazole phosphate spray containing 25%–40% (w / w) isopropanol in its formulation is stable, and its stability showed no significant difference after 6 months of accelerated testing (40°C / 75% RH).
[0178] Table 3. Accelerated test results of terdizolam phosphate spray prepared in Examples 1 and 8-9.
[0179]
[0180] Table 4. Accelerated test results of terdizolam phosphate spray prepared in Comparative Examples 2-4
[0181]
[0182]
[0183] Table 5 shows the accelerated test results of the terdizolam phosphate sprays prepared in Comparative Examples 5-6.
[0184]
[0185] Table 6. Accelerated test results of terdizolam phosphate spray prepared in Examples 12-13
[0186]
[0187]
[0188] Example 27 Antibacterial efficacy test
[0189] The antibacterial efficacy of the terdizolam phosphate sprays prepared in Examples 1 and 17-22 was tested according to (General Chapters 1105 and 1121 of Part IV of the Chinese Pharmacopoeia 2020).
[0190] Judgment criteria:
[0191]
[0192] The test results are shown in Table 7 below: Terizazole phosphate spray with a benzyl alcohol content of 1.2% to 2.2% (w / w), terizazole phosphate spray with a benzalkonium bromide content of 0.01% to 0.03% (w / w), and terizazole phosphate spray with a benzalkonium bromide content of 0.01% to 0.03% (w / w) all meet the requirements for antibacterial efficacy.
[0193] Table 7 Results of antibacterial efficacy test
[0194]
[0195]
[0196] Example 28 In vitro transdermal experiment
[0197] In vitro transdermal tests were conducted on the terdizolam phosphate sprays prepared in Examples 1, 14-16, and Comparative Examples 9-11.
[0198] In vitro transdermal testing was conducted using a vertical transdermal diffusion apparatus. The content of the test sample solution in the in vitro transdermal test was determined by high performance liquid chromatography (Chinese Pharmacopoeia 2020 Edition, Part IV, General Chapter 0512).
[0199] In vitro transdermal conditions: Receiving medium: pH 7.4 phosphate buffer (mix 250 ml of 0.2 mol / L potassium dihydrogen phosphate solution and 195.5 ml of 0.2 mol / L sodium hydroxide solution, dilute with water to 1000 ml, and shake well); Temperature: 32℃; Rotation speed: 600 rpm; Drug dosage: approximately 0.3 g; Skin: porcine skin; Sampling time: 2 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 20 h, 24 h.
[0200] In vitro transdermal data are shown in Table 8 below: Laureth nitrogen Terizazole spray with a ketone content of 0.5%–6% (w / w) has a cumulative permeability of over 5% in 24 hours, and lauryl nitrogen... When the ketone content is too low, it reduces the permeability, while when the content exceeds 6%, the cumulative permeability of terdiazole spray over 24 hours does not significantly increase. Menthol and isopropyl myristate have virtually no effect on the transdermal absorption of terdiazole phosphate spray.
[0201] Table 8
[0202]
[0203] Example 29: The therapeutic effect of terdizolam phosphate spray on deep skin tissue bacterial infection in mice.
[0204] This embodiment replicates a deep skin infection model by subcutaneously implanting methicillin-resistant Staphylococcus aureus into BALB / c mice. By detecting pathological changes and bacterial counts in the wound at different time points after drug administration, the efficacy of terdizolam phosphate spray on deep skin tissue bacterial infection in mice is tested.
[0205] 1. Test drug: Terizazole phosphate spray prepared in Example 1;
[0206] Comparative Example 9: Terizazole phosphate spray without transdermal absorption enhancer;
[0207] A blank solution (negative control) without terdizolam phosphate was prepared in the same manner as in Example 1.
[0208] Terizazole phosphate for injection (original formulation).
[0209] 2. Group setup: Sixty qualified SPF-grade BABL / c mice were selected, half male and half female, and randomly grouped according to body weight, as shown in Table 9.
[0210] Table 9
[0211]
[0212] 3. Modeling method: Hair on the backs of all animals in each group was shaved using a shaver. After disinfection with iodine and skin preparation, 2 mL of methicillin-resistant Staphylococcus aureus (MRSA) bacterial suspension (1×10⁻⁶) was added. 7 The animal was implanted subcutaneously in the back of a gauze pad soaked with CFU / mL (dissolved in 1.5% sodium carboxymethyl cellulose). The incision was then sutured with surgical sutures. The normal control group animals were not treated.
[0213] 4. Experimental methods: On the 4th day after administration and the day after the last administration, 6 animals were randomly selected from each group for bacterial counting and histopathological examination.
[0214] 5. Test Results:
[0215] (1) Effect on bacterial count in skin tissue
[0216] As shown in Table 10, compared with the normal control group, the bacterial count in the skin tissue of mice in the model control group was significantly increased before administration on day 4 and the day after the last administration (P≤0.01); compared with the model control group, the bacterial count in the skin tissue of mice in the terdizolam phosphate spray model group was significantly decreased before administration on day 4 (P≤0.01), and the bacterial count in the skin tissue of mice in the terdizolam phosphate spray model group without transdermal absorption enhancer and the terdizolam phosphate spray model group was significantly decreased the day after the last administration (P≤0.01 or P≤0.05); compared with the injectable terdizolam phosphate model group and the terdizolam phosphate spray model group without transdermal absorption enhancer, the bacterial count in the skin tissue of mice in the terdizolam phosphate spray model group was significantly decreased before administration on day 4 and the day after the last administration (P≤0.01).
[0217] Table 10 Effects of terdizolam phosphate spray on bacterial counts in mouse skin tissue ( n=6)
[0218]
[0219] Note: Compared with the normal control group ++ P≤0.01, compared with the model control group ** P≤0.01 or * P≤0.05, compared with the injectable terdizolamide phosphate model group and the terdizolamide phosphate spray model group without transdermal absorption enhancer. ## P≤0.01.
[0220] (2) Histopathological examination
[0221] like Figure 1 and Figure 2 As shown, no obvious abnormalities were observed in the skin tissue of the normal control group mice under microscopic observation before and the day after the last administration on the 4th day. In the model control group mice, fibrous connective tissue hyperplasia, vascular congestion / hemoptysis, and inflammatory cell infiltration were observed in the subcutaneous skin tissue. The injectable terdizolamide phosphate model group, the terdizolamide phosphate spray model group without transdermal absorption enhancer, and the terdizolamide phosphate spray model group all showed varying degrees of relief compared with the model control group.
[0222] As shown in Table 11, compared with the normal control group, the HE staining pathological scores of the skin tissue of mice in the model control group were significantly increased before administration on day 4 and the day after the last administration (P≤0.01); compared with the model control group, the HE staining pathological scores of the skin tissue of mice in the terdizolam phosphate spray model group and the terdizolam phosphate spray model group were significantly decreased before administration on day 4 and the day after the last administration (P≤0.01 or P≤0.05); compared with the injectable terdizolam phosphate model group and the terdizolam phosphate spray model group without the transdermal absorption enhancer, the HE staining pathological score of the skin tissue of mice in the terdizolam phosphate spray model group was significantly decreased (P≤0.01 or P≤0.05).
[0223] Table 11 HE staining pathological scores of skin tissue from model rats after treatment with terdizolamide phosphate spray ( n=6)
[0224]
[0225] Note: Compared with the normal control group ++ P≤0.01, compared with the model control group ** P≤0.01, compared with the injectable terdizolamide phosphate model group and the terdizolamide phosphate spray model group without transdermal absorption enhancer. ## P≤0.01.
[0226] Conclusions: (1) Changes in bacterial load and histopathology of mouse skin tissue at different time points can predict the severity of deep skin infection. The bacterial load in the skin tissue of the model control mice was significantly increased before administration on day 4 and the day after the last administration. Subcutaneous fibrous connective tissue hyperplasia, vascular congestion / hemoptysis, and inflammatory cell infiltration were observed, indicating successful model establishment. After administration of different dosage forms of the test drugs to the model mice, the bacterial load and lesion severity of the skin in each treatment group decreased to varying degrees.
[0227] (2) There was no significant difference between the terdizolamide phosphate spray model group without transdermal absorption enhancer and the injectable terdizolamide phosphate model group. The terdizolamide phosphate spray model group could significantly reduce the bacterial load and lesion degree of the skin tissue of the model mice, suggesting that the terdizolamide phosphate spray with added transdermal absorption enhancer has a significant therapeutic effect on deep skin tissue infection.
[0228] (3) The terdizolam phosphate spray model group showed significantly better inhibition of skin bacterial load and improvement of skin lesions than the injectable terdizolam phosphate model group and the terdizolam phosphate spray model group without transdermal absorption enhancer.
[0229] The embodiments described above are merely illustrative of several implementations of the present invention, and while the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the invention patent. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of the present invention, and these all fall within the protection scope of the present invention. Therefore, the protection scope of this invention patent should be determined by the appended claims.
Claims
1. A lisdexamfetamine spray characterized in that, Its raw and auxiliary materials include active ingredients, thickeners, lower alcohol solvents, transdermal absorption enhancers, antibacterial agents, pH adjusters, and water; The active ingredient is terdizodil or its ester, or a pharmaceutically acceptable salt thereof; The thickener is hydroxypropyl methylcellulose; The transdermal absorption promoter is lauric acid ketone; The hydroxypropyl methylcellulose content in the terdizolam spray is 0.05% to 0.4% by weight.
2. The atomizer of atomized timolol of claim 1, wherein, The hydroxypropyl methylcellulose is selected from one or more of hydroxypropyl methylcellulose E4M, hydroxypropyl methylcellulose K4M, hydroxypropyl methylcellulose F4M, hydroxypropyl methylcellulose K1500, hydroxypropyl methylcellulose K750, hydroxypropyl methylcellulose K250, and hydroxypropyl methylcellulose K100LV, with hydroxypropyl methylcellulose E4M being preferred. Preferably, the hydroxypropyl methylcellulose in the terdizolam spray contains 0.05% to 0.3% by weight, more preferably 0.05% to 0.2%, more preferably 0.08% to 0.2%, more preferably 0.08% to 0.15%, and even more preferably 0.09% to 0.12%. Preferably, the terdiazole spray has a dynamic viscosity of 20 mPa·s to 1000 mPa·s at 25°C, more preferably 50 mPa·s to 100 mPa·s.
3. The atomizer of tezdilamine according to claim 1, wherein The pH of the terdizolam spray is adjusted to 6.5-8.5, more preferably 7.0-8.5, and even more preferably 7.5-8.5, using a pH adjuster.
4. The terdizolam spray according to claim 1, characterized in that, The transdermal absorption enhancer is present in the terdizolam spray at a weight content of 0.5%-8.0%, preferably 0.5%-6.0%, more preferably 2.0%-6.0%, and even more preferably 2.0%-4.0%.
5. The terdizolam spray according to any one of claims 1-4, characterized in that, The lower alcohol solvent is one or more of a monohydric alcohol or a polyhydric alcohol; Preferably, the lower alcohol solvent is selected from one or more of isopropanol, ethanol, propylene glycol, and glycerol; Preferably, the lower alcohol solvent is a combination of a monohydric alcohol and a polyhydric alcohol, wherein the monohydric alcohol is preferably isopropanol and the polyhydric alcohol is preferably propylene glycol; the mass ratio of the monohydric alcohol to the polyhydric alcohol is preferably 16-27:
1. Preferably, the lower alcohol solvent in the terdiazole spray has a weight content of 20% to 42%, more preferably 25% to 40%, and even more preferably 30% to 38%.
6. The terdizolam spray according to any one of claims 1-4, characterized in that, The active ingredient is terdizolamide phosphate; and / or, The antibacterial agent is selected from at least one of methylparaben, ethylparaben, propylparaben, butylparaben, benzyl alcohol, phenoxyethanol, sodium benzoate, potassium sorbate, benzalkonium chloride, and benzalkonium bromide; and / or, The pH adjuster is selected from at least one of sodium hydroxide, potassium hydroxide, triethanolamine, diisopropanolamine, aminomethylpropanol, aminobutanetriol, and tetra-2-hydroxypropylethylenediamine; Preferably, the active ingredient in the terdiazole spray has a weight content of 0.1% to 5.0%, more preferably 0.5% to 3.0%, more preferably 0.5% to 2.5%, and even more preferably 1.5% to 2.5%. Preferably, the antibacterial agent in the terdiazole spray has a weight content of 0.01% to 3.0%, more preferably 0.01% to 2.2%.
7. The atomized atomoxetine spray of claim 1, wherein, The raw materials and excipients of the terdizolam spray, by weight percentage, include: Terizazole phosphate 0.5%–2.5%, Hydroxypropyl methylcellulose 0.05%–0.4%, Lower alcohol solvents 20%–42%, Transdermal absorption enhancer 0.5%–8.0%, Antibacterial agent 0.01%–3.0%, An appropriate amount of pH adjuster is used to adjust the pH of the terdizolam spray to 6.5–8.5; Add water to 100%; The alcohol solvent is a combination of a monohydric alcohol and a polyhydric alcohol, wherein the monohydric alcohol is isopropanol and the polyhydric alcohol is propylene glycol.
8. A process for the preparation of a pdeconexed spray as claimed in any one of claims 1 to 7, characterized in that, Includes the following steps: The thickener is added to the lower alcohol solvent, transdermal absorption enhancer, and antibacterial agent, and stirred until homogeneous. Then, some water and the active ingredient are added and stirred until homogeneous. The pH is adjusted with a pH adjuster, and finally, water is added to determine the weight, stirred until homogeneous, filtered, and filled to obtain the terdizolam spray.
9. The use of the terdizolam spray according to any one of claims 1-7 in the preparation of a medicament for treating acute bacterial skin and soft tissue infections.
10. The use of the terdizolam spray according to any one of claims 1-7 in the preparation of a medicament for treating skin tissue infections caused by methicillin-resistant Staphylococcus aureus.
